La vendita allo scoperto per NKGen Biotech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NKGen Biotech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NKGen Biotech (OTC:NKGN) Azioni, Report sulle vendite allo scoperto

NKGen Biotech

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

NKGen Biotech Inc

Before he became <a href="https://www.benzinga.com/personal-finance/25/02/43562104/bill-gates-was-the-richest-man-in-the-world-for-a-record-18-years-he-says-money-brings-freedom-but-beyond-that-its-the-same-hamburger">one of the wealthiest people</a> on the planet with Microsoft Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Bill Gates was just another Harvard undergrad, albeit one whose intelligence made a long-lasting impression on his professors.
One of them, Christos Papadimitriou, recalled thinking Gates was the smartest person he had ever encountered. But when Gates ditched academia to pursue business, Papadimitriou had just one reaction: &#8216;what a waste&#8217;.
What Happened: In the 1970s, Gates co-authored a paper on a mathematical problem called "pancake sorting" with Papadimitriou.
His unique solution slashed the number of necessary operations drastically and held the world record for decades.
But just two years later, when Papadimitriou called Gates to share the news that their paper had been accepted for publication in a prestigious journal, Gates had already changed course, relocating to New Mexico to concentrate on his <a href="https://www.benzinga.com/25/04/44627872/as-microsoft-turns-50-bill-gates-shares-the-original-code-that-started-it-all-that-was-the-revolution">software company</a>.
Speaking about the <a href="https://www.businessinsider.com/a-story-about-bill-gatess-intelligence-2015-11?utm_source=reddit.com">episode</a> at the ACM Awards several years later, Papadimitriou said:
"Two years later, I called to tell him our paper had been accepted to a fine math journal. He sounded eminently disinterested. He had moved to Albuquerque, New Mexico to run a small company writing code for microprocessors, of all things. I remember thinking: &#8220;Such a brilliant kid. What a waste.&#8221;
See Also: <a href="https://www.benzinga.com/news/25/04/44872914/microsoft-bets-big-on-carbon-removal-with-co280-inks-12-year-deal-targeting-u-s-pulp-and-paper-mills-emissions">Microsoft Bets Big On Carbon Removal With CO280, Inks 12-Year Deal Targeting U.S. Pulp And Paper Mills Emissions</a>
Why It Matters: Gates' early departure from Harvard to build Microsoft appeared like a diversion from academic glory. But it instead signalled the start of of one of the most dynamic and influential careers in the tech world.
While Papadimitriou saw Gates' re-orientation as a loss in the early days, <a href="https://www.benzinga.com/personal-finance/25/03/44548575/bill-gates-says-he-feared-microsoft-would-struggle-without-him-now-its-worth-3-trillion-and-thriving">history proved otherwise</a>.
Bill Gates may have walked away from math journals and complex theories, but not from problem-solving. His story demonstrates how intellectual ability can take many shapes and forms, and how a "waste" in one domain can transform into world-changing success in another.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/04/44891233/bill-gates-bought-his-daughter-a-16-million-horse-farm-as-a-graduation-gift-but-ex-wife-melinda-says">Bill Gates Bought His Daughter A $16 Million Horse Farm As A Graduation Gift — But Ex-Wife Melinda Says The Kids Were Raised Very &#8216;Middle Class&#8217;</a></li>
</ul>
Photo Courtesy: Alexandros Michailidis On Shutterstock.com

Entertainment

News

Success Stories

General

MSFT

Bill Gates' Harvard Professor Thought, 'What A Waste' When He Left Academia, But That 'Small Company' He Founded Changed The World

WIIM

NFLX

Netflix shares are trading higher after the company on Thursday reported a Q1 earnings beat and issued strong Q2 guidance.

Castellum, Inc. (NYSE-American: CTM) ("Castellum" or "CTM"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that it has entered into an amendment to a letter agreement to, among other things, reduce the principal balance on two notes payable to Robert Eisiminger by $2 Million, leaving an aggregate principal balance owed of $4 million.
In addition, the parties agreed to extend the maturity date on the remaining note payable until December 15, 2027. The full terms and conditions of the amendment to the letter agreement with Mr. Eisiminger are expected to be disclosed in a <a href="https://www.globenewswire.com/Tracker?data=NjjoJeQ47cZ4nvvLco_kj_DdY3jEBePqfMaxkfki1CSu2T5eOzhM_ZJ0WzKdM3z3mWxUa9rX2PYhFRRTT7hhcCRr7SBuAtz4UT5U4NoJcVPDuzlerYznElpmxS22vIfmDbeb9JY-gWKCcpNHYHMBd3iARdLmqCnQUur8bST3J535lNKP3Al_5YsXPYKbajukSVsKKpZkRRCjAFlNvRJqpw==">Form 8-K filed with the Securities and Exchange Commission</a> later today.

Castellum Reduces Debt By $2M And Extends Maturity Date To 2027

The Emergency Housing Vouchers program, a crucial support system for numerous Americans, is reportedly nearing a funding crisis. This could potentially result in one of&nbsp;the largest one-time losses of&nbsp;rental assistance in U.S. history.
What Happened: The program, initiated by former President Joe Biden in 2021, is expected to exhaust its funding by the end of 2026, according to a letter from the U.S. Department of Housing and Urban Development (HUD) <a href="https://apnews.com/article/trump-congress-housing-voucher-assistance-funding-cuts-26f9a716af6731e3c6445015488bab3a">seen</a> by The Associated Press.
The program, which was allocated $5 billion as part of the American Rescue Plan Act, aimed to aid individuals and families affected by homelessness, domestic violence, and human trafficking. It served a broad demographic, from children and seniors to veterans, across cities spanning San Francisco, Santa Clara, Dallas, Tallahassee and Florida.
However, the escalating cost of rent has accelerated the depletion of these funds. Last month, HUD advised groups distributing the funds to manage their programs with the expectation of no further funding.
HUD did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
Sonya Acosta, policy analyst at the Center on Budget and Policy Priorities, told the AP News, "To have it stop would completely upend all the progress that they've made&#8230;And then you multiply that by 59,000 households.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/general/space/25/04/44891901/elon-musks-spacex-will-launch-dragon-cargo-capsule-as-part-of-crs-32-mission-to-iss" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s SpaceX Will Launch Dragon Cargo Capsule As Part Of CRS-32 Mission To ISS &#8211; Benzinga</a>
Why It Matters: The Emergency Housing Vouchers program&#8217;s funding crisis comes against a backdrop of ongoing housing affordability issues. In 2025, the&nbsp;Trump administration reportedly planned to cut <a href="https://www.benzinga.com/real-estate/25/02/44040257/trump-administration-looking-to-slash-hud-workers-tackling-housing-crisis-could-deepen-affordability-problems">as many as 50% </a>of the jobs at HUD, potentially exacerbating affordability problems.
Despite efforts to address the housing shortage, including a proposal to construct nearly&nbsp;<a href="https://www.benzinga.com/news/25/03/44376829/trump-administration-plans-to-construct-nearly-4-million-affordable-homes-on-federal-land">4 million affordable housing units </a>on federal land, the housing market has seen a disparity between sellers and buyers due to affordability concerns. This has led to an increase in inventory and potential price reductions, as reported by&nbsp;<a href="https://www.benzinga.com/news/25/04/44885312/for-sale-but-no-takers-the-us-housing-markets-awkward-standoff">Zillow</a>.
With the Emergency Housing Vouchers program&#8217;s funding nearing exhaustion, the housing crisis could potentially worsen, affecting thousands of Americans. The program's future now depends on Congress, which has the authority to allocate more funds through the federal budget. However, given the current Republican majority's emphasis on cutting federal spending, the likelihood of securing additional funding remains uncertain.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/44884419/trump-offered-an-olive-branch-twice-this-weekend-says-kevin-oleary-its-time-for-chinas-xi-to-take-it" target="_blank" rel="noreferrer noopener">Trump Offered An Olive Branch Twice This Weekend, Says Kevin O&#8217;Leary—It&#8217;s Time For China&#8217;s Xi To Take It &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Nearly 60,000 American Households Face Eviction Threat As Emergency Housing Vouchers Program Runs Out Of Funds: Report

Earnings

Earnings Beats

Bank of Hawaii Q1 2025 GAAP EPS $0.97 Beats $0.89 Estimate, Sales $169.865M Beat $169.238M Estimate

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) with a Buy and lowers the price target from $75 to $50.

Price Target

Analyst Ratings

NDRA

Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $50

New parents are raising concerns that President Donald Trump&#8217;s tariffs could significantly drive up the cost of baby care products. What Happened: Sam Rutledge and his wife, who are expecting a baby in mid-July, have fast-tracked their purchases of baby gear due to the tariff announcement in early April.
The couple has bought two strollers, a car seat, a nursery glider, a crib, and a high chair, all of which are made overseas. &#8220;These are all pretty expensive under normal conditions, but when it became clear tariffs were coming we decided to buy them in case they became prohibitively expensive,&#8221; Rutledge said, according to <a href="https://fortune.com/article/new-parents-worried-trump-tariffs-will-make-having-baby-prohibitively-expensive/">a</a> report by Fortune.
The&nbsp;Juvenile Products Manufacturers Association, a&nbsp;U.S. trade group, estimates that&nbsp;90% of the core baby&nbsp;care products and their parts are made in Asia, with the majority coming from China. The tariffs, ranging&nbsp;from 10% for imports from&nbsp;most countries to 145% for&nbsp;imports from China, could significantly increase the cost for new parents.
Steven Dunn, CEO of Munchkin Inc., has halted orders from China and instituted a hiring freeze at the company&#8217;s California headquarters in response to the tariffs. Dunn expects Munchkin will run out of some products within three months. &#8220;There is no possibility of being able to pass on those tariffs&#8221; to customers in the form of price increases, he said.
See Also:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/04/44891509/bitcoin-crosses-key-barrier-dogecoin-spikes-ethereum-flat-on-easter-sunday-popular-influencer-says-btc-needs-to-breach-88804-for-a-bullish-breakout" target="_blank" rel="noreferrer noopener">Bitcoin Crosses Key Barrier, Dogecoin Spikes, Ethereum Flat On Easter Sunday: Popular Influencer Says BTC Needs To Breach $88,804 For A Bullish Breakout &#8211; Grayscale Bitcoin Mini Trust (BTC) Common uni</a>
Many baby brands and companies have declined to comment on the tariffs.&nbsp;The Juvenile Products Manufacturers Association&nbsp;has&nbsp;asked the Trump administration for&nbsp;a tariff exemption, arguing that&nbsp;baby products are essential for&nbsp;children&#8217;s well-being.
Why It Matters: The tariffs, part of Trump&#8217;s strategy to stimulate domestic investment by companies seeking to evade import taxes, took effect in early April. The&nbsp;<a href="https://www.benzinga.com/news/global/25/04/44632479/retail-stocks-slammed-as-trumps-tariff-plan-sends-shockwaves-through-sector?">retail sector</a>&nbsp;was hit hard, with stocks under heavy selling pressure as Wall Street digested the tougher-than-anticipated tariff plan.
Former Secretary of the Treasury Lawrence H. Summers described <a href="https://www.benzinga.com/25/04/44622754/tariffs-are-most-expensive-and-masochistic-could-cost-30-trillion-to-the-economy-erasing-300k-per-family-explains-former-treasury-secretary-larry-summers">the tariffs as the "most expensive and masochistic" </a>move by the U.S., which could roil the economy, erasing trillions of dollars. According to him, the stock futures fell 2-3% after Trump&#8217;s announcement, erasing about $1.5 trillion, and the market had already priced in some of the impact.
With the majority of baby care products being imported from Asia, particularly China, the tariffs could significantly increase the cost for new parents, making essential baby care items unaffordable. Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44891607/el-salvadors-nayib-bukele-proposes-swapping-us-deported-venezuelans-with-nicolas-maduros-political-prisoners-vene" target="_blank" rel="noreferrer noopener">Nayib Bukele Proposes Swapping US-Deported Venezuelans With Nicolas Maduro&#8217;s &#8216;Political Prisoners&#8217;</a></li>
</ul>
Photo Courtesy: Joshua Sukoff on Shutterstock.com

Politics

Economics

Trump's Tariffs Add Financial Strain for New Parents Amid Rising Baby Gear Costs

Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.15 by 8.7 percent. This is a 27.55 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $829.00 million which missed the analyst consensus estimate of $831.34 million by 0.28 percent. This is a 5.74 percent increase over sales of $784.00 million the same period last year.

Comerica Q1 2025 GAAP EPS $1.25 Beats $1.15 Estimate, Sales $829.00M Miss $831.34M Estimate

B. Riley Securities analyst Craig Ellis downgrades Axcelis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) from Buy to Neutral and lowers the price target from $80 to $50.

Downgrades

ACLS

B. Riley Securities Downgrades Axcelis Technologies to Neutral, Lowers Price Target to $50

On Thursday, April 17, U.S. markets closed mixed as investors balanced progress in trade talks with ongoing concerns about interest rates. Optimism followed positive comments on trade negotiations, but uncertainty remained about future deals. While some sectors saw gains, the broader market experienced declines over the week. Traders are focused on upcoming trade discussions and potential actions from the central bank.
In economic data, U.S. housing starts decreased by 11.4% month-over-month to an annualized rate of 1.324 million in March. Initial jobless claims fell by 9,000 to 215,000 in the second week of April, better than the expected 225,000. The Philadelphia Fed Manufacturing Index dropped by 39 points to -26.4 in April, well below the expected 2.
Most sectors on the S&amp;P 500 closed higher, led by energy, consumer staples, and real estate, while information technology and healthcare ended lower.
The Dow Jones Industrial Average declined 1.33% to 39,142.23, the S&amp;P 500 rose 0.13% to 5,282.70, and the Nasdaq Composite slid 0.13% to close at 16,286.45.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 fell 1.30% to close at 34,279.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.</li>
<li>Australian markets are closed for the Easter holiday.</li>
<li>India&#8217;s Nifty 50 was up 1.11% at 24,119.25, and Nifty 500 rose 1.45% to 21,994.95.</li>
<li>China&#8217;s Shanghai Composite rose 0.45% to 3,291.43, while Shanghai Shenzhen CSI 300 gained 0.33% to 3,784.88.</li>
<li>Hong Kong markets are closed for the Easter holiday.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>European markets closed for the Easter holiday.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 2.91% at $62.15/bbl, and Brent was down 2.80% at $66.05/bbl.</li>
<li>Oil prices dropped on Monday amid positive U.S.-Iran talks and concerns over an economic slowdown caused by tariffs. Lower liquidity and fears of reduced fuel demand heightened market volatility.</li>
<li>Natural Gas fell 0.96% to $3.216.</li>
<li>Gold was trading higher by 2.34% at $3,406.26, Silver was up 1.12% to $32.835, and Copper rose 0.87% to $4.7803.</li>
<li>Gold prices hit a new record on Monday, rising due to a weaker dollar, geopolitical tensions, and uncertainty surrounding U.S. Federal Reserve policy.        </li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.98%, S&amp;P 500 futures declined 1.12% and Nasdaq 100 futures fell 1.20%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index slipped 1.29% to 99.19, USD/JPY was down 1.07% to 140.65, and USD/AUD fell 0.18% to 1.5653.</li>
<li>The dollar fell sharply on Monday, hitting decade-lows against the Swiss franc and yen, as concerns grew over President Trump&#8217;s plans to challenge the independence of the Federal Reserve.</li>
</ul>
Photo by FOTOGRIN via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Gold Rallies To Record, Dollar Drops - Global Markets Today While US Slept

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) with a Buy and lowers the price target from $75 to $60.

CING

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $60

Mizuho analyst Uy Ear initiates coverage on Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) with a Outperform rating and announces Price Target of $51.

Initiation

TECX

Mizuho Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $51

<ul>
<li>ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis</li>
<li>Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets</li>
<li>ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process</li>
<li>Special Meeting of Stockholders for both companies to be held May 13, 2025</li>
</ul>

ALMS

SLRN

Alumis And ACELYRIN Finalize Amended Merger Deal; New Terms Offer Greater Stake For ACELYRIN Shareholders

TORONTO, April 21, 2025 /CNW/ - Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNL#TSX">CNL</a>) ("Collective" or the "Company") is pleased to announce changes in the executive management of the Company effective immediately with the appointment of Ned Jalil as Chief Executive Officer, and former CEO Omar Ossma retaining his role as President and continuing to perform his same duties within the day-to-day operations of the Company.
 &nbsp;

Management

TSX:CNL

Collective Mining Names Ned Jalil CEO, Effective Immediately

Morgan Stanley analyst Benjamin Swinburne downgrades Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Overweight to Equal-Weight and lowers the price target from $37 to $32.

Morgan Stanley Downgrades Warner Music Gr to Equal-Weight, Lowers Price Target to $32

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule").
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, 2025, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until April 13, 2025, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company's request for continued listing.
The Notice has no immediate effect on the listing or trading of the Company's common shares.
The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.

Government

Regulations

AFMD

Affimed Receives Nasdaq Notice Over Low Share Price, Has Until October to Regain Compliance

Chicago Fed President Austan Goolsbee has voiced serious concerns over President Donald Trump's recent remarks about removing Federal Reserve Chair Jerome Powell. What Happened: Trump's comments, made following <a href="https://fortune.com/2025/04/16/jerome-powell-tariffs-inflation-economy/">Powell's speech</a> at the Economic Club of Chicago, reignited a long-standing debate over the President's power to remove Federal Reserve leaders.
Goolsbee warned that such an action could severely undermine the credibility of the U.S. central bank, with far-reaching consequences for economic stability, as reported <a href="https://fortune.com/article/chicago-fed-president-austan-goolsbee-trump-terminate-jerome-powell-undermine-fed-credibility/">by</a> Fortune on Monday.
Trump has repeatedly criticized Powell for not cutting interest rates quickly enough in response to economic conditions, particularly following his controversial tariff policies.
Powell has argued that the tariff increases announced by Trump have significantly impacted inflation and economic growth, which led to his warnings.
Trump has blamed Powell for not acting swiftly enough to ease interest rates, which he believes are necessary to counter the negative economic effects of his policies.
See Also: <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44883642/peter-schiff-rings-alarm-after-foreign-investors-dump-6-5-billion-in-us-equities-in" target="_blank" rel="noreferrer noopener">Peter Schiff Rings Alarm After Foreign Investors Dump $6.5 Billion In US Equities In A Week, Quips &#8216;Trump Thought Tariffs Would Bring Capital Into America&#8217;</a>
This conflict has drawn attention. Goolsbee, echoing the concerns of many economists, cautioned that removing Powell could set a dangerous precedent that could erode trust in the Fed.
"I strongly hope that we do not move ourselves into an environment where monetary independence is questioned," Goolsbee stated, highlighting the importance of keeping the Federal Reserve free from political influence.
Why It Matters: Trump&#8217;s criticism of Powell and his intention to terminate him have been a topic of concern for some time. Trump <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44861571/donald-trump-blasts-too-late-and-wrong-fed-chair-powell-but-polymarket-traders-doubt-his-termination-will-come-fast-enough">lashed out at Powell</a> for the Federal Reserve&#8217;s reluctance to cut interest rates.
This was followed by <a href="https://www.benzinga.com/markets/25/04/44883756/warren-foresees-market-turmoil-if-trump-dismisses-feds-powell-if-powell-can-be-fired-by-trump-it-will-crash-markets">Senator Elizabeth Warren&#8217;s warning</a> about a potential stock market collapse if Trump decides to fire Powell.
Investment strategists have also&nbsp;<a href="https://www.benzinga.com/news/25/04/44882256/trumps-threat-to-fire-powell-could-shake-us-financial-markets">warned</a>&nbsp;that Trump&#8217;s potential attempt to dismiss Powell could rattle U.S. financial markets and undermine central bank independence. Furthermore,&nbsp;<a href="https://www.benzinga.com/25/04/44888232/trumps-top-economic-adviser-kevin-hassett-says-white-house-is-exploring-options-to-fire-fed-chair-jerome-powell-the-president-and-his-team-will-continue-to-study">White House National Economic Council chair Kevin Hassett</a>&nbsp;confirmed that the Trump administration is exploring ways to remove Powell, adding to the uncertainty. Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44891314/dhl-says-its-suspending-global-shipments-to-us-valued-more-than-800-as-customs-updates-cause-multi-day-transit-de" target="_blank" rel="noreferrer noopener">DHL Says It&#8217;s Suspending Global Shipments To US Valued More Than $800 As Customs Updates Cause Multi-Day Transit Delays</a></li>
</ul>
Photo courtesy: Domenico Fornas / Shutterstock.com

Chicago Fed President Expresses Concern Over Trump's Intention To Dismiss Jerome Powell

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Market Perform and lowers the price target from $47 to $42.

FITB

Keefe, Bruyette & Woods Maintains Market Perform on Fifth Third Bancorp, Lowers Price Target to $42

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains First Finl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>) with a Market Perform and lowers the price target from $38 to $36.

FFIN

Keefe, Bruyette & Woods Maintains Market Perform on First Finl Bankshares, Lowers Price Target to $36

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and raises the price target from $19 to $20.

PSTV

Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20

Health Care

Press Releases

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

Comments

NKGen Biotech

Vendite allo scoperto

NKGen Biotech (OTC:NKGN) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO